Residue and recurrence in percutaneous cryoablation for cT1 renal tumor: Clinical utility and feasibility of salvage cryoablation with iodized oil marking

Percutaneous cryoablation of renal cell carcinomas in patients with Von Hippel‐Lindau disease: Functional and oncological outcomes

“…We retrospectively analyzed the records of 14 VHL patients who underwent PCA between February 2014 and June 2022 at our institution. Transcatheter arterial embolization (TAE) was performed prior to PCA in order to mark the tumors, as previously reported 4 . Percutaneous cryoablation was performed using 17‐gauge cryoneedles (IceRod®︎; Galil Medical, Yokneam, Israel) and a common cryoablation system (CryoHit®︎; Galil Medical, Yokneam, Israel) under CT guidance or 0.3‐T MRI.…”

“…Transcatheter arterial embolization (TAE) was performed prior to PCA in order to mark the tumors, as previously reported. 4 Percutaneous cryoablation was performed using 17-gauge cryoneedles (IceRod®︎; Galil Medical, Yokneam, Israel) and a common cryoablation system (CryoHit®︎; Galil Medical, Yokneam, Israel) under CT guidance or 0.3-T MRI. Assessment of technique efficacy, residual tumor, local tumor recurrence, and eGFR preservation was conducted according to our previously published protocol.…”